OraSure Technologies Elects Jack Kenny to the Board of Directors
OraSure Technologies (NASDAQ: OSUR) has elected Jack Kenny to its Board of Directors, effective September 9, 2024. Kenny, with over 30 years of experience in leadership roles in the in vitro diagnostics, molecular, and lab services industries, will serve as a Class I Director with an initial term expiring at OraSure's 2025 Annual Meeting of Stockholders. His addition brings the board to seven members.
Kenny is the former CEO of Meridian Bioscience, where he led a successful turnaround. His extensive experience includes executive roles at Siemens Healthcare, Becton Dickinson, Danaher , and Quest Diagnostics. OraSure's Board Chair, Mara Aspinall, expressed confidence in Kenny's ability to contribute significant value and industry expertise to the company's ongoing efforts to strengthen its foundation, elevate core growth, and accelerate profitability.
OraSure Technologies (NASDAQ: OSUR) ha eletto Jack Kenny nel suo Consiglio di Amministrazione, con effetto dal 9 settembre 2024. Kenny, con oltre 30 anni di esperienza in ruoli di leadership nei settori del diagnostica in vitro, molecolare e servizi di laboratorio, servirà come Direttore di Classe I con un mandato iniziale che scade all'Assemblea Annuale degli Azionisti di OraSure nel 2025. La sua aggiunta porta il consiglio a sette membri.
Kenny è l'ex CEO di Meridian Bioscience, dove ha guidato un recupero di successo. La sua vasta esperienza include ruoli esecutivi in Siemens Healthcare, Becton Dickinson, Danaher e Quest Diagnostics. Il Presidente del Consiglio di OraSure, Mara Aspinall, ha espresso fiducia nella capacità di Kenny di contribuire con un valore significativo e competenza del settore agli sforzi in corso dell'azienda per rafforzare la propria base, elevare la crescita fondamentale e accelerare la redditività.
OraSure Technologies (NASDAQ: OSUR) ha elegido a Jack Kenny para su Junta Directiva, efectivo el 9 de septiembre de 2024. Kenny, con más de 30 años de experiencia en roles de liderazgo en las industrias de diagnósticos in vitro, molecular y servicios de laboratorio, servirá como Director de Clase I con un mandato inicial que expira en la Asamblea Anual de Accionistas de OraSure en 2025. Su incorporación lleva el consejo a siete miembros.
Kenny es el ex CEO de Meridian Bioscience, donde lideró un exitoso giro. Su amplia experiencia incluye roles ejecutivos en Siemens Healthcare, Becton Dickinson, Danaher y Quest Diagnostics. La presidenta de la Junta de OraSure, Mara Aspinall, expresó confianza en la capacidad de Kenny para contribuir con un valor significativo y experiencia en la industria a los esfuerzos continuos de la compañía para fortalecer su base, elevar el crecimiento básico y acelerar la rentabilidad.
OraSure Technologies (NASDAQ: OSUR)는 Jack Kenny를 이사회에 선임했으며, 이는 2024년 9월 9일부터 효력이 발생합니다. Kenny는 체외 진단, 분자 및 실험실 서비스 산업에서 30년 이상의 리더십 경험을 가진 인물로, 클래스 I 이사로서의 임기는 OraSure의 2025년 주주총회에서 만료됩니다. 그의 합류로 이사회는 총 일곱 명이 되었습니다.
Kenny는 Meridian Bioscience의 전 CEO로, 성공적인 회생을 이끌었습니다. 그의 광범위한 경력에는 Siemens Healthcare, Becton Dickinson, Danaher, Quest Diagnostics에서의 경영직이 포함됩니다. OraSure의 이사회 의장인 Mara Aspinall은 Kenny가 회사의 기반을 강화하고 핵심 성장을 높이며 수익성을 가속화하기 위한 지속적인 노력에 중요한 가치를 제공할 수 있을 것이라는 신뢰를 표명했습니다.
OraSure Technologies (NASDAQ: OSUR) a élu Jack Kenny à son Conseil d'Administration, avec effet au 9 septembre 2024. Kenny, avec plus de 30 ans d'expérience dans des rôles de leadership dans les secteurs des diagnostics in vitro, moléculaires et des services de laboratoire, exercera en tant qu'Administrateur de Classe I pour un mandat initial qui expirera lors de l'Assemblée Générale Annuelle des Actionnaires d'OraSure en 2025. Son addition porte le conseil à sept membres.
Kenny est l'ancien PDG de Meridian Bioscience, où il a mené un redressement réussi. Son expérience étendue comprend des fonctions exécutives chez Siemens Healthcare, Becton Dickinson, Danaher et Quest Diagnostics. La présidente du Conseil d'OraSure, Mara Aspinall, a exprimé sa confiance dans la capacité de Kenny à apporter une valeur significative et une expertise sectorielle aux efforts continus de l'entreprise pour renforcer sa base, élever sa croissance essentielle et accélérer sa rentabilité.
OraSure Technologies (NASDAQ: OSUR) hat Jack Kenny in seinen Verwaltungsrat gewählt, und zwar mit Wirkung zum 9. September 2024. Kenny, der über 30 Jahre Erfahrung in Führungspositionen in den Bereichen in-vitro-Diagnostik, molekulare und Laborservices verfügt, wird als Direktor der Klasse I fungieren, dessen Amtszeit zunächst mit der Jahreshauptversammlung der Aktionäre von OraSure im Jahr 2025 endet. Seine Ergänzung bringt die Zahl der Vorstandsmitglieder auf sieben.
Kenny ist der ehemalige CEO von Meridian Bioscience, wo er einen erfolgreichen Wandel führte. Seine umfassende Erfahrung umfasst Führungsrollen bei Siemens Healthcare, Becton Dickinson, Danaher und Quest Diagnostics. Mara Aspinall, die Vorsitzende des OraSure-Vorstands, äußerte Vertrauen in Kennys Fähigkeit, dem Unternehmen wertvolle Perspektiven und branchenspezifisches Fachwissen zu liefern, um die laufenden Bemühungen zur Stärkung der Basis, zur Steigerung des Kerngeschäfts und zur Beschleunigung der Rentabilität voranzutreiben.
- Addition of Jack Kenny, an experienced industry leader, to the Board of Directors
- Kenny's extensive experience in diagnostics and lab services industries
- Potential for fresh perspectives and strengthened leadership with the new board member
- None.
BETHLEHEM, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions today announced the election of Jack Kenny to its Board of Directors, effective September 9, 2024. With the addition of Mr. Kenny, OraSure’s Board of Directors currently has seven members.
Mr. Kenny is the former Chief Executive Officer for Meridian Bioscience, where he led the company’s turnaround before it was acquired. He has more than 30 years of experience with leadership roles in the in vitro diagnostics, molecular, and lab services industries. He will serve as a Class I Director with an initial term expiring at OraSure’s 2025 Annual Meeting of Stockholders.
“We recognize the significant value and industry expertise that Jack will contribute, and we are pleased to continue to strengthen our Board with his participation,” said Mara Aspinall, Chair of the Board of Directors of OraSure. “Under our leadership team led by President and CEO Carrie Eglinton Manner, we have made meaningful progress on our journey to strengthen our foundation, elevate our core growth, and accelerate our profitability. We look forward to the value Jack will add to the company.”
Before his tenure at Meridian, Mr. Kenny served as Senior Vice President and General Manager, North America, with Siemens Healthcare and as Vice President and General Manager, U.S. Region, for Becton Dickinson, Diagnostic Systems. Prior to that, he held executive roles at Danaher Corporation and Quest Diagnostics.
Mr. Kenny’s operational experience in the diagnostics field is broad, including product management, commercial leadership, and acquisition integration. He holds a bachelor’s degree in management from Kettering University.
About OraSure Technologies
OraSure Technologies, Inc. (“OraSure”) transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. OraSure, together with its wholly-owned subsidiary, DNA Genotek Inc., is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, commercial entities, and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.
Forward-Looking Statement
This press release contains certain forward-looking statements. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: our ability to satisfy customer demand; ability to reduce our spending rate, capitalize on manufacturing efficiencies and drive profitable growth; ability to achieve the anticipated cost savings as a result of our business restructuring, including from insourcing third party manufacturing and exiting microbiome services; ability to market and sell products, whether through our internal, direct sales force or third parties; impact of significant customer concentration in the genomics business; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products; ability to manufacture or have manufactured products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the FDA or other regulators; the impact of the novel coronavirus (“COVID-19”) pandemic on OraSure's business, supply chain, labor force, ability to successfully develop new products, validate the expanded use of existing collector products, receive necessary regulatory approvals and authorizations and commercialize such products for COVID-19 testing, and demand for our COVID-19 testing products ; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; ability to meet increased demand for OraSure’s products; impact of replacing distributors; inventory levels at distributors and other customers; ability of OraSure to achieve its financial and strategic objectives and continue to increase its revenues, including the ability to expand international sales and the ability to continue to reduce costs; impact of competitors, competing products and technology changes; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid or urine testing, collection or other products; market acceptance and uptake of microbiome informatics, microbial genetics technology and related analytics services; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention or other agencies; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of our products; impact of contracting with the U.S. government; impact of negative economic conditions; ability to maintain sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of OraSure’s stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; cybersecurity breaches or other attacks involving our systems or those of our third-party contractors and IT service providers; the impact of terrorist attacks, civil unrest, hostilities and war ; and general political, business and economic conditions, including inflationary pressures and banking stability. These and other factors that could affect our results are discussed more fully in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2023, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.
| Investor Contact: | Media Contact: |
| Jason Plagman | Amy Koch |
| Vice President, Investor Relations | Director, Corporate Communications |
| investorinfo@orasure.com | media@orasure.com |
FAQ
Who is Jack Kenny and why was he elected to OraSure Technologies' Board of Directors?
When will Jack Kenny's term on OraSure Technologies' (OSUR) Board of Directors expire?
How many members are now on OraSure Technologies' (OSUR) Board of Directors after Jack Kenny's election?
What is OraSure Technologies' (OSUR) current focus according to the press release?
